Piper Sandler Maintains Overweight on DexCom, Raises Price Target to $150
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has maintained an Overweight rating on DexCom (NASDAQ:DXCM) and increased the price target from $135 to $150.
December 19, 2023 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reaffirmed DexCom's Overweight rating and raised the price target from $135 to $150, indicating a positive outlook on the stock.
The increase in price target by Piper Sandler suggests a bullish outlook on DexCom's future performance, which could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100